ADMA

ADMA BiologicsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$12.50

+61.1% vs current

Most likely

Base case

45%

Probability

Target price

$8.90

+14.7% vs current

B-

Bear case

25%

Probability

Target price

$6.50

-16.2% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Post-earnings tone is mixed-to-negative. ADMA closed at $10.08 on May 6, 2026 and then at $8.47 on May 7, 2026, a 15.97% one-day drop, with May 8, 2026 intraday trading around $8.17 on StockAnalysis, which suggests the market focused more on the guidance cut and long-term-guide withdrawal than on margin and cash-flow strength. Initial trusted-news coverage in the packet is thin, and delayed analyst revision breadth is still limited; visible summaries show target cuts rather than upgrades, so this remains a monitoring-style setup instead of a confirmed bullish re-rating.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-06eventQ1 print reset FY2026 expectations and reframed the story as a trough-recovery setupHigh impact

On May 6, 2026 ADMA reported Q1 revenue of $114.5 million, ASCENIV revenue up 28% year over year, adjusted net income of $40.7 million, adjusted EBITDA of $59.7 million, and operating cash flow of $58 million, but it also cut FY2026 outlook to $530-$560 million of revenue, $170-$200 million of adjusted net income, $265-$300 million of adjusted EBITDA, and withdrew long-term guidance because of competitive U.S. plasma-product and IG market dynamics [#8-K-2026-05-06].

2026-06-30catalystASCENIV demand stabilization versus channel dislocation is the key near-term checkHigh impact

Management said ASCENIV demand fundamentals remained strong, with record utilization, record new patient starts, broader prescriber adoption, and an April second-quarter run rate in-line with first-quarter direct sales, while the pressure was concentrated in distributor ordering and BIVIGAM amid an IG market reset [#8-K-2026-05-06]. If that April read-through holds, the post-earnings selloff may have over-discounted a temporary dislocation.

2026-12-31catalystFirst full year of yield-enhanced production can still support margin resilienceHigh impact

ADMA's filings say 2026 is the first full year of yield-enhanced production, with 20%+ higher ASCENIV and BIVIGAM yields from the same plasma input and management still pointing to sustained margin expansion even after the guidance reset [#10-K-2026-02-25] [#10-Q-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology